Welcome to our dedicated page for Akero Therapeutics news (Ticker: AKRO), a resource for investors and traders seeking the latest updates and insights on Akero Therapeutics stock.
Akero Therapeutics, Inc. (Nasdaq: AKRO) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, developing efruxifermin (EFX) for metabolic dysfunction-associated steatohepatitis (MASH) and related metabolic liver diseases. This news page aggregates company announcements, clinical updates and financial disclosures so readers can follow how Akero’s development programs progress over time.
Akero’s news flow is heavily driven by data from its clinical trials. Regular press releases cover results and analyses from the Phase 2b HARMONY and SYMMETRY studies, which evaluate EFX in patients with pre-cirrhotic (F2–F3) MASH and compensated cirrhosis (F4) due to MASH, respectively. Updates often include histology outcomes, non-invasive fibrosis markers, and AI-based digital pathology findings that the company uses to characterize the antifibrotic activity of EFX.
Investors and clinicians can also find announcements related to the global Phase 3 SYNCHRONY program, including enrollment milestones and planned timing of readouts for SYNCHRONY Histology, SYNCHRONY Outcomes and SYNCHRONY Real-World. In addition, Akero regularly reports quarterly financial results, business updates, and participation in major healthcare and liver disease conferences, where management presents new data and analyses.
Another key category of news involves corporate and strategic developments. Akero has announced an Agreement and Plan of Merger under which it is expected to become a wholly owned subsidiary of Novo Nordisk A/S, subject to stockholder and regulatory approvals. Readers who follow AKRO news can track updates on this proposed transaction alongside ongoing clinical and scientific disclosures. Bookmark this page to quickly access the latest company-issued information, from peer-reviewed publication announcements to conference presentations and regulatory-related communications.
Akero Therapeutics (Nasdaq: AKRO) announced a $25 million equity investment from Pfizer at $9.90 per share and a $100 million term loan facility from Hercules Capital. The financing aims to support the ongoing development of efruxifermin (EFX), targeting nonalcoholic steatohepatitis (NASH). If fully drawn, the loan extends Akero's cash runway to Q3 2024, two years beyond the anticipated HARMONY study readout. Pfizer will acquire approximately 6.7% of Akero's shares and join a newly formed Scientific Advisory Board.
Akero Therapeutics (Nasdaq: AKRO) announced it will present findings at the Keystone Symposium on Tissue Fibrosis and Repair, June 12-16, 2022. The presentations will showcase the potential of efruxifermin (EFX) to reverse fibrosis in patients with nonalcoholic steatohepatitis (NASH). Notably, data from the Phase 2a BALANCED trial demonstrates significant reductions in liver collagen synthesis markers. Chief Scientific Officer Tim Rolph emphasized EFX's promise as an antifibrotic therapy, with patients showing substantial improvement after just 16 weeks of treatment.
Akero Therapeutics (Nasdaq: AKRO) announced its participation in the Jefferies Global Healthcare Conference on June 9, 2022, at 4:00 p.m. E.T. This clinical-stage company focuses on innovative treatments for serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), which currently lacks approved therapies. Their lead candidate, efruxifermin (EFX), is designed for convenient weekly subcutaneous dosing and is under evaluation in two Phase 2b clinical trials. The presentation will be webcasted live, with archived replays available on their website.
Akero Therapeutics (Nasdaq: AKRO) is progressing well in its clinical trials for efruxifermin (EFX), targeting non-alcoholic steatohepatitis (NASH). The company reported Q1 2022 financial results, with cash reserves of $165.4 million expected to sustain operations into Q3 2023. Research and development expenses surged to $20.5 million, reflecting ongoing clinical trials. Total operating expenses reached $26.1 million, compared to $15.1 million in Q1 2021. Akero anticipates reporting results from its Phase 2b HARMONY study in Q3 2022.
Akero Therapeutics (Nasdaq: AKRO) announced its participation in two upcoming investor conferences. The BofA Securities 2022 Healthcare Conference includes a fireside chat on May 11 at 8:40 a.m. PT in Las Vegas, while the H.C. Wainwright Annual Global Life Sciences Conference offers on-demand viewing of a fireside chat on May 24 at 7:00 a.m. ET. Webcasts will be accessible on their website, with archived replays available later. Akero is focused on developing innovative treatments for serious metabolic diseases, particularly NASH.
Akero Therapeutics (Nasdaq: AKRO) reported its financial results for the fourth quarter and full year 2021, indicating cash reserves of $188.3 million, sufficient to fund operations into Q3 2023. The company is on track to release results from the Phase 2b HARMONY study for its lead candidate, efruxifermin (EFX), in Q3 2022. Increased R&D expenses of $81.8 million for 2021 are attributed to the EFX program. Akero has made advancements in manufacturing capabilities, including a new drug formulation in a dual-chamber syringe device for self-administration.
Akero Therapeutics (Nasdaq: AKRO) has completed enrollment in its Phase 2b HARMONY study for efruxifermin (EFX), targeting non-alcoholic steatohepatitis (NASH). This follows promising Phase 2a results where 48% of patients showed fibrosis improvement after 16 weeks. The Phase 2b trial involves a longer 24-week treatment period, aiming for fibrosis regression. Preliminary results are expected in Q3 2022. EFX is designed for convenient dosing and may become a leading NASH treatment if proven effective.
Akero Therapeutics (Nasdaq: AKRO) announced its participation at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 10:30 a.m. E.T. The live presentation will be accessible via the investor relations section of their website, with archived replays available afterward.
Akero is focused on developing therapies for serious metabolic diseases, particularly non-alcoholic steatohepatitis (NASH). Their lead candidate, efruxifermin (EFX), is undergoing Phase 2b trials and aims to provide a groundbreaking treatment option for patients.
Akero Therapeutics (Nasdaq: AKRO) announced its participation in the Evercore ISI 4th Annual HealthCONx Virtual Conference on December 2 at 3:30 p.m. E.T. This event will include a management fireside chat, which will be accessible via a live webcast on the company's investor relations page. Akero Therapeutics focuses on developing treatments for serious metabolic diseases, specifically targeting non-alcoholic steatohepatitis (NASH). Its lead candidate, efruxifermin (EFX), is currently undergoing two Phase 2b trials aimed at assessing its effectiveness in various patient groups.
On November 12, 2021, Akero Therapeutics (Nasdaq: AKRO) reported promising results from a post-hoc analysis of its Phase 2a BALANCED study of efruxifermin (EFX) for non-alcoholic steatohepatitis (NASH). After 16 weeks, 87% (35 of 40) of EFX-treated patients showed improvements in steatohepatitis, while 80% (32 of 40) demonstrated fibrosis improvement. The findings were presented at The Liver Meeting of the American Association for the Study of Liver Diseases. Akero is optimistic about the upcoming Phase 2b studies and the potential for EFX to become a leading treatment for NASH.